Trial site
General Oncological Hospital Of Kifissia Agioi Anargyroi
Kifissia, 145 64, GreeceNot linked to an institution yet
- 20running trials
- 9closed trials
The trials here
What the 29 trials at this site are about, from their registry records.
- Phase
- Phase 321 trials
- Phase 26 trials
- Phase 2/32 trials
- Status
- Recruiting13 trials
- Completed9 trials
- Active, not recruiting4 trials
- Not yet recruiting3 trials
- Lead sponsor
- AbbVie3 trials
- Merck Sharp & Dohme LLC3 trials
- AstraZeneca2 trials
- Hellenic Institute for the Study of Sepsis2 trials
- Mirati Therapeutics Inc.2 trials
- and 16 more
Running trials
Not yet recruiting
Substudy to Evaluate the Potential Treatment Effect of the ABBV-7066 (risankizumab/ABBV-701) Combination Compared to Each Respective Monotherapy in Subjects with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis
2026-525960-16-00· Phase 2· AbbVie Deutschland GmbH & Co. KG· Source
Recruiting
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
NCT07834346· Phase 3· Hellenic Institute for the Study of Sepsis· Source
Recruiting
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
NCT07697456· Phase 2· AbbVie· Source
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206· Phase 3· AbbVie· Source
Recruiting
A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex
NCT06087536· Phase 2· Omnix Medical Ltd· Source
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· Phase 3· AstraZeneca· Source
Recruiting
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
2025-520555-89-00· Phase 3· Amgen Inc.· Source
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· Phase 3· AstraZeneca· Source
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463· Phase 2· AbbVie· Source
Recruiting
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
2023-507853-13-00· Phase 2· Eli Lilly & Co.· Source
Active, not recruiting
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
NCT06687369· Phase 3· mAbxience Research S.L.· Source
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· Phase 3· Shanghai Henlius Biotech· Source
Recruiting
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
2023-509340-10-00· Phase 3· OSE Immunotherapeutics· Source
Recruiting
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842· Phase 3· Ipsen· Source
Active, not recruiting
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.
NCT05636176· Phase 3· Novo Nordisk A/S· Source
Recruiting
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
NCT05303532· Phase 3· Astrazeneca AB· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· Phase 3· Shanghai Henlius Biotech· Source
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· Phase 2/3· Mirati Therapeutics Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error